SCHEMBL3276646

SCHEMBL3276646

CCCCCCCC/C=C\CCCCCCCCOc1ccc(C=O)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 1/20 0.67
▸ MAPT P10636 10/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ LMNA P02545 3/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.55
▸ HTT P42858 2/20 0.55
▸ ALDH1A1 P00352 12/20 0.55
▸ TSHR P16473 1/20 0.54
▸ CYP2C9 P11712 3/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ HPGD P15428 7/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ HSP90AA1 P07900 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7272285 0.93 FDPS (0.55) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL1259277 0.93 FDPS (0.55) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL1259270 0.93 FDPS (0.55) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL30360546 0.93 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL8907835 0.93 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL2818009 0.93 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL30360548 0.93 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL5689116 0.93 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL10417162 0.93 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1
SCHEMBL8310250 0.93 FDPS (0.77) FDPSMAPTSMN1; SMN2LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087524-A1 Flavour Improving Substances GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2010-04-08 — — US claimed
EP-2124630-A1 FLAVOUR IMPROVING SUBSTANCES Givaudan Nederland Services B.V. (NL) 2009-12-02 — — EP claimed
WO-2008105652-A1 FLAVOUR IMPROVING SUBSTANCES GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-09-04 — — WO claimed
EP-4680039-A1 COMPOSITIONS FOR REDUCING OFF NOTES AND USES THEREOF DSM-Firmenich AG (CH) 2026-01-21 — — EP disclosed
WO-2024251755-A1 COMPOSITIONS FOR REDUCING OFF NOTES AND USES THEREOF DSM-FIRMENICH AG (CH) 2024-12-12 — — WO disclosed
US-20230148641-A1 FLAVOR COMPOSITION FIRMENICH SA (CH) 2023-05-18 — — US disclosed
EP-4125427-A1 FLAVOR COMPOSITION Firmenich SA (CH) 2023-02-08 — — EP disclosed
WO-2021198199-A1 FLAVOR COMPOSITION FIRMENICH SA (CH) 2021-10-07 — — WO disclosed
US-20100087524-A1 Flavour Improving Substances GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2010-04-08 — — US disclosed
US-20100087524-A1 Flavour Improving Substances GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2010-04-08 — — US disclosed
EP-2124630-A1 FLAVOUR IMPROVING SUBSTANCES Givaudan Nederland Services B.V. (NL) 2009-12-02 — — EP disclosed
EP-2124630-A1 FLAVOUR IMPROVING SUBSTANCES Givaudan Nederland Services B.V. (NL) 2009-12-02 — — EP disclosed
WO-2008105652-A1 FLAVOUR IMPROVING SUBSTANCES GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-09-04 — — WO disclosed
WO-2008105652-A1 FLAVOUR IMPROVING SUBSTANCES GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-09-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087524-A1 Flavour Improving Substances SDHA, DLAT, LPO FDPS 222/4885MAPT 3152/4885SMN1; SMN2 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback